This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Fast-Acting Migraine Treatment Highlighted During National Migraine Awareness Month

Dr. Cady continued, “The Phase 4 study results confirm that SUMAVEL DosePro can be an important component of a migraine patient’s therapeutic toolbox.  I believe it is important for physicians to provide their patients with treatment options to help manage the variety of attacks that patients experience.”

In a Phase 4 open-label, multicenter U.S. study more than 200 adult patients diagnosed with migraine and taking triptan therapy were enrolled to evaluate overall satisfaction, confidence and preference for SUMAVEL DosePro, as well as efficacy and safety, in treating multiple migraine attacks.  Key results from the study include:

  • Patients reported greater overall satisfaction after treating multiple migraine attacks with SUMAVEL DosePro compared to their current triptan therapy, which was predominantly oral triptans
    • Freedom from pain was achieved in 61% of migraine episodes within 2 hours
    • In 33% of migraine episodes, pain relief was achieved in 15 minutes; in 70% of episodes it was achieved in 30 minutes; and in 85% and 86% of episodes it was achieved in 1 and 2 hours
  • A subset of patients (90) identified as needing a change in their migraine therapy based on their Migraine Assessment of Current Therapy (Migraine-ACT) score showed dramatic improvements in treatment satisfaction after using SUMAVEL DosePro
    • Patients showed a clinically relevant improvement in overall treatment satisfaction (from 17% at baseline to 62%) and confidence (from 22% at baseline to 58%) by the end of the treatment period
    • Provided effective relief from migraine pain and associated symptoms
    • Efficacy, satisfaction and confidence remained consistent during use for multiple migraine attacks

By including SUMAVEL DosePro as a treatment option, which currently represents less than 5% of the triptan prescriptions, these patients can access:

  • Migraine pain relief beginning within 10 minutes for some patients*
  • First-of-its-kind needle-free delivery system providing injectable sumatriptan option when oral therapies may be an impractical treatment option (i.e. migraine with vomiting or nausea)
  • An alternative for patients with rapid onset migraines because subcutaneous sumatriptan delivery is quickly absorbed

Roger Hawley, Chief Executive Officer of Zogenix, concluded, "Our mission at Zogenix is simple and clear.  We are passionately striving to make a difference for patients with moderate to severe migraine attacks through education and by offering a unique way to treat migraines.  We believe that SUMAVEL DosePro fills a significant unmet medical need for migraine patients and has the potential to provide economic benefits for employers who are paying the high costs from ineffective treatments and the corresponding loss of productivity."

*In two well-controlled clinical trials (N=1104) with patients experiencing moderate or severe pain and one or more migraine symptoms, the efficacy of subcutaneous sumatriptan vs. placebo was evaluated. In these clinical trials, 16% of patients achieved relief within 10 minutes vs. 4% placebo; 70% of patients achieved relief at one hour vs. 22% placebo; and 82% of patients achieved relief at two hours vs. 39% placebo.

(1)  American Migraine Foundation; http://www.americanmigrainefoundation.org/whatismigraine.aspx#burden.

(2)  National Migraine Treatment Survey on behalf of the National Headache Foundation, March 2010.

About SUMAVEL DosePro

SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.

2 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs